MRK vs RPRX
Merck & Co. vs Royalty Pharma plc — AI-powered side-by-side comparison
VS
RPRX
Royalty Pharma plc
56
Watch
| Metric | MRK | RPRX |
|---|
| AI Score |
70
|
56
|
| Price |
$130.34
|
$57.79
|
| P/E Ratio |
103.53×
|
23.98×
|
| ROE |
34.7%
|
11.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
89.4%
|
| Debt / Equity |
1.29×
|
1.31×
|
| Dividend Yield |
2.6%
|
1.6%
|
| RSI (14) |
64.5
|
49.6
|
| Beta |
0.207
|
0.425
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for MRK versus RPRX.
MRK leads by 14 points.
MRK scores 70/100 (Buy) versus RPRX at 56/100 (Watch).
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
RPRX Committee View
60% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 40.9 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 40.9 is expensive by classic value standards — Value
- EPS declining -15.9% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical